Opioid Use Disorder After Injury: Legal Implications for PI Attorneys

James Wong — Founder & Pharmacist, LienScripts | March 29, 2026 | 8 min read

When a PI patient develops opioid use disorder as a consequence of injury-related opioid therapy, it creates additional compensable damages. This guide covers the legal framework, medication evidence, and demand strategies for OUD in personal injury cases.

Opioid use disorder (OUD) that develops as a consequence of opioid therapy prescribed for accident injuries is a compensable harm — an additional category of damages beyond the underlying physical injury — and the medication evidence in the pharmacy record is often the most objective documentation of this harm available to PI attorneys. The pharmacy timeline showing the progression from acute opioid prescriptions to dose escalation, tolerance, and ultimately medication-assisted treatment (MAT) with buprenorphine or methadone tells a story of cascading injury consequences that defendants are legally responsible for.

• OUD is a DSM-5 diagnosed medical condition characterized by compulsive opioid use despite harmful consequences, and an estimated 8-12% of patients prescribed opioids for chronic pain develop OUD (Vowles et al., Pain, 2015; CDC Morbidity and Mortality Weekly Report)
• The eggshell plaintiff doctrine applies: even if the patient had predisposing risk factors for OUD, the defendant takes the plaintiff as found and is liable for the full extent of harm including the OUD that developed from injury-related opioid therapy
• LienScripts covers all OUD treatment medications on pharmacy lien — including buprenorphine, naltrexone, and naloxone — and documents the treatment timeline in the MERIT (Medication Evaluation & Rationale for Injury Treatment) report
• According to James Wong, PharmD, founder of LienScripts, "The pharmacy record is the most objective evidence of OUD progression — it shows exactly when prescriptions increased, when the patient was transitioned to MAT, and how long treatment has continued"
• PubMed meta-analyses demonstrate that trauma patients receiving opioids for more than 90 days have significantly elevated OUD risk, establishing the causal chain from injury to disorder (Edlund et al., Clinical Journal of Pain, 2014)

The Legal Framework: OUD as Consequential Harm

OUD developing after injury-related opioid therapy fits established tort principles:

Proximate Cause

The causal chain is straightforward: (1) defendant caused the accident, (2) accident caused injuries, (3) injuries required opioid therapy, (4) opioid therapy caused OUD. Each link is supported by medical evidence. The foreseeability of OUD after extended opioid therapy is well-established in the medical literature, satisfying the proximate cause requirement.

Eggshell Plaintiff Doctrine

Some patients are more susceptible to OUD based on genetic factors, prior mental health conditions, or family history of addiction. Under the eggshell plaintiff doctrine, the defendant takes the plaintiff as found. If the accident set in motion the chain of events that led to OUD — even in a patient with predisposing factors — the defendant bears full liability for the resulting harm.

Superseding Cause Defense

Defense counsel may argue that the prescriber's opioid prescribing decisions (not the accident) caused the OUD. This argument generally fails because: (1) the prescribing was a foreseeable response to the injuries the defendant caused, and (2) the medical treatment of injuries does not constitute a superseding cause that breaks the chain of causation.

[!KEY] OUD after injury is not a preexisting condition and should never be characterized as one. It is a new medical condition caused by the treatment of injuries the defendant inflicted. The damages are additive — the patient is entitled to compensation for the underlying injuries AND for the OUD that developed as a consequence.

Medication Evidence of OUD Progression

The pharmacy record provides objective documentation of OUD development:

Early Warning Signs in the Record

• Dose escalation — progressive increases in opioid strength or quantity over time
• Early refill requests — prescriptions filled before the expected run-out date
• Multiple opioid prescriptions — concurrent prescriptions from different providers (though this also occurs in legitimate multi-provider care)
• Supplemental prescriptions — benzodiazepines or sleep medications added to manage opioid side effects

MAT Initiation as Diagnostic Confirmation

The pharmacy record showing a transition to buprenorphine (Suboxone, Subutex, Sublocade) or naltrexone (Vivitrol) for OUD treatment is objective evidence that a medical professional diagnosed OUD. Unlike subjective reports, the prescription is a concrete clinical act with documentation in the medical record.

Ongoing MAT as Continuing Damage

Continued buprenorphine or naltrexone prescriptions over months or years document the chronic nature of OUD. This is not a condition that resolves quickly — the SAMHSA recommends MAT for a minimum of 12 months, and many patients require years of treatment. Each month of MAT documented in the pharmacy record is a month of ongoing harm.

[!TIP] Request a complete pharmacy history from the patient's insurance and all pharmacies (not just the lien pharmacy) for the period from the accident date forward. The full medication timeline — including prescriptions from multiple providers — tells the complete OUD development story.

Damage Categories for OUD

OUD after injury supports multiple damage categories:

Past Medical Expenses

• MAT medications (buprenorphine, naltrexone, naloxone)
• Addiction medicine physician visits
• Inpatient or outpatient treatment programs if applicable
• Comfort medications during opioid-to-buprenorphine transition
• Drug screening and monitoring costs

Future Medical Expenses

• Ongoing MAT medication costs (potentially years of buprenorphine therapy)
• Ongoing addiction medicine follow-up
• Relapse prevention and monitoring
• Potential need for higher levels of care if relapse occurs

Pain and Suffering

• The withdrawal experience during MAT induction
• Daily burden of medication-dependent sobriety
• Psychological impact of an addiction diagnosis
• Social stigma and relationship consequences

Loss of Earning Capacity

• Restrictions on employment due to MAT (some safety-sensitive positions)
• Reduced cognitive function during active OUD or early MAT
• Time lost to treatment appointments and medication management

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The pharmacy lien record creates an unbroken medication timeline from the first post-accident opioid prescription through the MAT transition. This chronological evidence is far more persuasive than a retrospective diagnosis because it was generated in real time as the clinical situation evolved."

Demand Package Strategy

Building the OUD Narrative

1. Establish the baseline — Document that the patient had no history of OUD or opioid use before the accident
2. Show the progression — Use the pharmacy timeline to demonstrate escalating opioid therapy
3. Identify the transition — Highlight the point where the treating physician diagnosed OUD and initiated MAT
4. Quantify ongoing treatment — Calculate past and future MAT costs, physician monitoring, and associated expenses
5. Include the MERIT report — LienScripts generates a MERIT report showing the complete medication chronology with clinical context

Expert Support

Consider retaining an addiction medicine specialist to provide a declaration or testimony establishing:

• The causal relationship between the accident-related opioid therapy and OUD development
• The expected duration and cost of MAT
• The patient's prognosis for recovery
• The impact of OUD on the patient's quality of life and functional capacity

[!KEY] Do not concede the OUD narrative to the defense. Present OUD as evidence of the defendant's liability — the accident caused injuries so severe that the resulting opioid therapy produced a secondary medical condition requiring its own long-term treatment. This framing increases both special and general damages.

Insurance Barriers and Pharmacy Lien Coverage

OUD treatment faces significant insurance barriers:

• Prior authorization for buprenorphine and extended-release naltrexone
• Quantity limits that restrict dosing flexibility during stabilization
• Formulary restrictions favoring less effective generic formulations
• Stigma-driven denials where insurers question the OUD diagnosis or treatment necessity

LienScripts covers all MAT medications on pharmacy lien, ensuring uninterrupted treatment access regardless of insurance status. The lien accrues against the PI settlement, aligning the pharmacy's interests with the case outcome.

FAQs

Related Resources

• Buprenorphine Transition After Injury: Attorney Guide
• Opioid Prescribing Guidelines in Personal Injury Cases
• Naloxone Co-Prescribing in PI Cases
• What Is a Pharmacy Lien?